Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is a Healthcare company (Biotechnology) with a market capitalization of $297M. The Maz Rating grades it against the other companies in its sector.
Kyverna Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.70, Kyverna Therapeutics, Inc. trades at 2.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -86.9%, return on invested capital of -98.5% and a free cash flow yield of -50.9%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 7.01. Over the past 52 weeks the share price ranged from $4.50 to $13.67, with a beta of 2.13.
Kyverna Therapeutics, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.